Ruben A. Mesa, MD, discusses the JAK2 inhibitor pacritinib, which led to better symptom control and improved cytopenias in patients with myelofibrosis. Read more about PERSIST-1 here.
PERSIST-1: Pacritinib Shakes Up the Current Myelofibrosis Treatment Landscape
Recent Articles
Ropeginterferon alfa-2b-njft Approved for Polycythemia Vera
The U.S. Food and Drug Administration (FDA) has approved ropeginterferon alfa-2b-njft for the treatment of adult patients with polycythemia vera (PV).
This decision is based...
Are Hospital Leaders Doing Enough to Address Supply Chain Issues?
A poll by consulting firm Sage Growth Partners on behalf of inventory management platform Syft found that among 100 organizations, 93% have taken action...
EZM0414 Granted Fast Track Designation for DLBCL
The U.S. Food and Drug Administration (FDA) has granted fast track designation to oral SETD2 inhibitor EZM0414 as an investigational agent for the treatment...
Disease Detectives: CLL in Asia
Researchers continue to investigate why rates of chronic lymphocytic leukemia remain lower in Asian populations.
In the United States, chronic lymphocytic leukemia (CLL) accounts for...
Editor’s Corner: Ill Communication
“Any questions?” is a phrase that is often situated at the end of a clinic visit. The phrase was also made famous during the...
Current Issue
November 2021 Bonus ASH Annual Meeting Preview Edition
This issue offers a behind-the-scenes look at this year's annual meeting, and more.